retatrutide phase 2 obesity trial results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide Phase 2 NEJM Trial:

Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway

Importantly, absolute rate reductions for all effectiveness outcomes were larger with increasing severity of frailty. Researchers conducted a retrospective cohort study of older adults aged at least 65 years diagnosed with type 2 diabetes who initiated an SGLT2 inhibitor, GLP-1 receptor agonist or a DPP-IV inhibitor

That may create the opportunity for more employers to offer coverage to the members that are experiencing obesity related complications

Longevity and cellular-signaling peptides such as Epithalon and NAD+ should be handled with the same cold-chain discipline as growth-hormone secretagogues like CJC-1295 No-DAC and the Tesamorelin / Ipamorelin stack

Brown meat on medium heat instead of burning it

Acute aflatoxin B 1 -induced hepatic and cardiac oxidative damage in rats: Ameliorative effects of morin